CXCR2 and colorectal carcinoma: We suggest combination therapy of CXCR2, TGFBR, or MMP9 inhibitors with ICB could broaden immunotherapy responsiveness in CRC patients, especially in those with pervasive neutrophil infiltration and TGFβ activity.